Near-patient or point-of-care testing (POCT) has generated substantial interest among healthcare providers during the past several years [J] 5 Devices based on disposable microelectrodes that measure electrolytes, urea, glucose, and hematocrit in small volumes of undiluted whole blood have been reported to provide sufficient reliability, precision, and accuracy for clinical use [2] [3] [4] . Similar methods for additional analytes can be expected in the near future [5, 6] . The most obvious advantage of these devices is the ability to rapidly (in <5 mm) provide a biochemical test value from a small whole-blood sample. Despite evidence that these devices clearly work, numerous questions persist regarding POCT [1] . For example, management of patients' data (billing, entry into medical records and medical information systems) is not automatic or always straightforward for these devices, which may lead to problems such as lack of a permanent record and loss of charges. Second, nonlaboratory personnel, whose primary responsibilities may be in a very hectic environment such as the emergency department (ED), are usually the operators of POCT, and may not be familiar with or always comply with preanalytical procedures, quality control (QC), quality assurance, or regulatory policies. Finally, the relation between the increased cost of a POCT device and a beneficial impact on care of patients is unclear. Because these devices generally have costs at least 2-3 times higher per patient than the central laboratory cost [3, 7, 8] , it is important to determine whether faster laboratory values will result in a positive clinical or economic outcome.
One area of the healthcare system in which faster laboratory results might result in beneficial patient outcome by allowing faster clinical decisions and decreased length of stay (LOS) is the ED [3, 4, [9] [10] [11] . However, the only studies involving the ED to date are based on retrospective surveys of ED clinicians who did not actually use POCT results for clinical decisions [4, 11] . One currently available POCT device is the i-STAT (i-STAT Corp., Princeton, NJ), which can provide values for Na, K, Cl, blood urea nitrogen (BUN), glucose (Gluc), hematocrit (Hct), and A repeat limit/panic value policy was established so that samples producing values exceeding these limits were repeated in the ED and the blood sample was also sent to the central laboratory.
LOS STUDY DESIGN
Triage time (time of initial patient interview by a registered nurse) and discharge time (e.g., patient released to home, admitted to hospital) were entered into the hospital information system for every ED patient. LOS, defined as the length of time between triage and discharge, was the end point examined during the study. The study was divided into three periods: control, experimental, control. During the first control periodDecember 11, 1994, throughJanuary 16, 1995-all biochemical testing from the ED was performed in the customary way, through the central laboratory.
In the experimental periodFebruary 28 through April 4, 1995-the ED exclusively used the i-STAT for its available tests. The one exception was that patients coming through the ED for prearranged hospital admission did not have i-STAT testing performed (such patients often have laboratory tests ordered by the ED as a courtesy to the admitting floor). In the second control period-April 6-24, 1995-all testing was again performed by the central laboratory.
Between January 16 and February 28, 1995, we attempted to begin the experimental period but encountered several problems that necessitated retraining i-STAT operators (see Results). To ensure full usage of the i-STAT during the experimental period, we removed from the ED computer "quick" ordering system the ability to order a central laboratory "Chem 6" profile (Na, K, Cl, Gluc, CO2, and creatinine).
Creatinine and total CO2 are not available on the i-STAT EC6+ cartridge, so ED physicians were allowed to order them from the central laboratory at no additional charge. In analyzing LOS during the experimental period, we both included and excluded patients with either creatinine or total CO, ordered from the central laboratory or with other chemistry tests performed in the central laboratory.
Printouts
of i-STAT results were attached to the patient's ED chart and were available to all physicians who saw the patient and to the admitting floor. Twice a day, i-STAT results were downloaded from the devices to a personal computer and then entered into the laboratory information system for billing purposes as well as to become a part of the patient's permanent record.
ED patientsubgroups. Laboratory information systeln records were searched for all ED patients seen in each study period to determine which patients had one or more of the i-STAT 
Results

1-STAT PERFORMANCE IN THE ED
Before the initial training of ED personnel on use of the i-STAT, laboratory personnel first evaluated its performance. The precision and accuracy were consistent with previously reported studies (data not shown) [2] [3] [4] 11] . 
ED POPULATION CHARACTERISTICS AND LOS
Because of the problems with i-STAT Hct values, only ED patients with one or more of Na, K, Cl, BUN, or Gluc tests ordered were included in the study-eligible ED patient population. During the two control periods, a total of 8841 patientS were seen in the ED, of whom 2918 (33%) had at least one of the above tests ordered from the central laboratory ( Table 2 ). The median LOS for the 5923 ED patients without these laboratory tests ordered was 105 mm, whereas the median LOS was 201 mm for the study-eligible ED patients who had these biochemical tests ordered (Table 2) . LOS for the two control periods were not significantly different (P = 0.4) and thus are combined for all comparisons with the experimental period. During the 5-week experimental period, 2067 (34%) ED patients were study-eligible; their median LOS was 209 mm, whereas that for the 3963 study-ineligible ED patients was 109 mm ( Table 2 ). (Table 2 ), routine use of the i-STAT device clearly did not decrease the overall LOS, or its distribution (Fig. 2) , when other central laboratory testing was performed. During the experimental period, only 91 of the 1722 patients of LOS for all patients and study-eligible patients during the control and experimental periods.
(5.3%) with i-STAT testing had no other central laboratory tests performed; for these patients, the median LOS was 164 mm (Fig. 1) . Interestingly, only 35 of the 2918 study-eligible patients (1.2%) during the combined control periods had no other central laboratory testing besides a Chem 6 or 7 (Chem 7 = Chem 6 plus BUN); their median LOS was 159 mm. Because of the small number of patients with no other central laboratory tests, the 95% confidence interval for the difference between experimental and control periods is -28 mm to 24 mm. Given that the LOS of ED patients admitted to the hospital may be affected by factors beyond the control of the ED and because these patients do not have to wait for results of all central laboratory tests before discharge to the floor, we examined how use of the i-STAT might impact the LOS for patients discharged home vs those admitted to the hospital. During both the control and experimental periods, 5 5-56% of ED studyeligible patients were admitted to the hospital and 37-38% of these patients were discharged home ( Table 3 ). The LOS did not differ significantly between the experimental and control periods for those patients admitted or for those sent home (Table 3) .
EFFECTS OF VARIOUS PRESENTING CONDITIONS
The acuity, number, and type of diagnostic procedures, as well as the number of physician consultations, will vary considerably according to the presenting symptoms of an ED patient. Therefore, we examined the impact of the i-STAT device on the LOS for groups of ED patients with different presenting symptoms ( Table 3 ). The LOS for these categories of patients varies considerably (e.g., chest pain vs abdominal pain). However, of the presenting symptoms categories with at least 30 patients in both the control and experimental periods, in none did the use of the i-STAT significantly improve the median LOS (Table 3 ) Presenting symptom groups with <30 patients in one or more of the study periods; these symptoms include altered level of consciousness, sickle cell crises, arrhythmias, renal failure, hypertension, osmolality/electrolyte abnormality, vaginal bleeding, back pain, psychiatric, rule-out anemia, and hypotension. URI, upper respiratory infection; UTI, urinary tract infection.
or significantly change the 10th or 90th percentile of LOS: The smallest one-sided P-value was 0.18.
Discussion
We prospectively examined the impact of POCT for Na, K, Cl, Gluc, and BUN on patient LOS in the ED by instituting a 5-week experimental period during which i-STAT values were used for clinical decision making. Because it produces technically valid results [2] [3] [4] and is easy to operate, the i-STAT is an ideal device for prospectively determining whether rapid bedside results would decrease LOS in the ED. LOS in the ED for 1722 patients during this experimental period was compared with the LOS for 2918 patients during two control periods, one preceding and one following the experimental period. We found that use of i-STAT results in the ED for clinical decisions failed to shorten ED patient LOS, regardless of final disposition, presenting symptoms, or the presence or absence of other central laboratory testing. The impact of laboratory value turnaround time on total ED LOS is uncertain, but the general perception is that "faster is better." Two recent studies [4, ii] by leading them away from one patient to another, thus extending the actual time for physicians to act on laboratory results [10] .However, some portion of the longer LOS when biochemical tests are ordered is undoubtedly due to the patients being "sicker," requiring other nonlaboratory procedures and additional physician consultations. Our results are in agreement with a study that prospectively examined the impact of a dedicated ED stat laboratory [10] but differ from two recent studies that addressed the potential impact of the i-STAT by asking ED physicians whether i-STAT results would have expedited clinical decisions for patients they had previously treated without knowledge of the i-STAT results [4, 11] . Despite the different conclusions and approaches used, there are remarkable similarities in the ED populations of these earlier studies [4, 11] and ours. Like our population, 55% of the Stanford University ED population was admitted [4] . Furthermore, ED patients released home in the Stanford study had a median LOS of 215 mm, the same as the median LOS of 215 mm for our patients discharged home. In both of the retrospective studies [4, Ii] , the distribution of patients by presenting symptom is remarkably similar to our findings in much larger populations.
For instance, much like our findings (Table 3) , chest pain was the presenting symptom in 13%, abdominal pain in 7-10%, shortness of breath in 11-12%, and nausea/vomiting in 5-7% of all patients in these two studies [4, 11] . In the study by Tsai et to speculate whether the availability of rapid electrolyte testing led to more rapid discharge and less additional testing for some patients during the experimental period. Do ED physicians preventively order more tests, knowing they must wait anyway for results of the tests they initially require? If so, use of the i-STAT might decrease unnecessary central laboratory testing. An alternative hypothesis would be that, when results are immediately available, the tests would be ordered more frequently simply because there will be no time delay. Our study cannot address these possibilities; however, as POCT test menus expand, the number of ED patients whose laboratory testing can be done immediately will increase. An unexpected observation from this study was the poor reliability of i-STAT Hct values despite intense efforts at retraining i-STAT operators. Conductance methods produce slightly higher values than particle counting methods [11] and can be markedly affected by large alterations in electrolyte and protein concentrations [15] . In some clinical settings, e.g., pediatric perfusion procedures, these interferences can be clinically very significant [15] . However, none of the cases of discrepant i-STAT Hct values we saw reflected marked hypo-or hyperprotemnemia, and we can only ascribe these discrepant values to improper sample mixing. i-STAT samples were obtained from tubes by use of a syringe, as in previously published evaluations of the i-STAT [3, 4, 11] . For Hct discrepancies as large as 19% PCV, it is likely that ED personnel failed to mix the contents of either the tubes or the syringes when there were time delays between drawing the blood and performing the i-STAT analysis. This raises the question of whether numerous nonlaboratory operators in a busy environment such as the ED will always maintain awareness of preanalytical factors such as proper sample mixing, regardless of how simple the device is to operate. One approach to overcoming this potential problem is to have one or two dedicated operators at a central location in the ED [3] . However, this could substantially add to the cost and might itself introduce transport and analysis time delays. We did not perform a cost analysis in this study, preferring first to determine whether POCT would have a beneficial impact on patient care. Our results emphasize the importance of examining the impact of POCT in a particular setting before its institution and also raise the question as to whether some tests on the i-STAT can really be made "operator-proof" in a nonlaboratory setting.
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